Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA:600267)

SHA:600267 Revenue

Zhejiang Hisun Pharmaceutical had revenue of 2.05B CNY in the quarter ending September 30, 2026, a decrease of -23.47%. This brings the company's total for the last twelve months to 9.15B, down -11.94% year-over-year. In the year 2025, Zhejiang Hisun Pharmaceutical had annual revenue of 10.55B with 2.03% growth. That makes Zhejiang Hisun Pharmaceutical the 6,352nd largest company in the world by revenue and 875th in China.

• Revenue (ttm): 9.15B
• Revenue Growth: -11.94%
• P/S Ratio: 1.70
• Revenue / Employee: 1.05M
• Employees: 8,751
• Market Cap: 15.52B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Manufacturing 6.50B 62.3%
• Pharmaceutical Business 3.90B 37.4%
• Others 18.93M 0.2%
• CMO/CDMO/CRO Business 7.80M 0.1%

By Geography

Chart

• China 9.76B 93.6%
• Foreign 663.11M 6.4%

Fiscal year ended Dec 31, 2025 See the full SHA:600267 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	10.55B	209.39M	2.03%
Dec 31, 2024	10.34B	-32.82M	-0.32%
Dec 31, 2023	10.37B	-1.66B	-13.82%
Dec 31, 2022	12.04B	-99.78M	-0.82%
Dec 31, 2021	12.14B	782.07M	6.89%

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 3, 2026

Data Sources Report a data error